Evidence map›Paper›PMID 41365879›Full record

ArticleNature communications2025

Geminin inhibits DNA replication licensing by sterically blocking CDT1-MCM2 interactions.

Joshua Tomkins, Lucy V Edwardes, Sarah V Faull, Matthew Peach, Peter J Gillespie, Vera Leber, Anna Schmidt, Halil Bounoua, Nicholas Sim, Rosa Camarillo and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joshua Tomkins *Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID http://orcid.org/0009-0007-8875-2977
Lucy V Edwardes *Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Sarah V FaullInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Matthew PeachInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-9024-2289
Peter J GillespieDivision of Molecular, Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK.
Vera LeberInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Anna SchmidtInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID http://orcid.org/0009-0003-6777-2566
Halil BounouaInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Nicholas SimInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-5710-3762
Rosa CamarilloInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
J Julian BlowDivision of Molecular, Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK.ORCID http://orcid.org/0000-0002-9524-5849
Alexis R BarrInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK. a.barr@lms.mrc.ac.uk.ORCID http://orcid.org/0000-0002-6684-8114
Anna BarnardDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, UK. a.barnard@imperial.ac.uk.ORCID http://orcid.org/0000-0002-1327-3417
Christian SpeckInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK. chris.speck@imperial.ac.uk.ORCID http://orcid.org/0000-0001-6646-1692

Funding

Cancer Research UK (CRUK) DRCNPG-May21\100006Wellcome Trust
6 · The paper itself

Abstract

DNA replication is tightly regulated to occur once per cell cycle, with the MCM2-7 helicase loaded onto replication origins only during G1-phase. In higher eukaryotes, geminin negatively regulates this process during S-, G2- and M-phases by binding the essential licensing factor CDT1. Although geminin's function is crucial for genomic stability, its inhibitory mechanism remains elusive. Here, we utilise a fully reconstituted human DNA replication licensing assay to dissect geminin's role. AlphaFold modelling provides structural insights into an N-terminal CDT1-binding helix of geminin, which proves essential for inhibition. Structural docking of the CDT1-geminin complex into the ORC-CDC6-CDT1-MCM2-7 (OCCM) assembly shows that geminin's long coiled-coil domain sterically clashes with the MCM2 C-terminus, rather than directly blocking CDT1 binding to ORC-CDC6-MCM2-7. Shortening the coiled-coil preserves geminin dimerisation and CDT1 binding but abolishes inhibition, confirming its mechanistic role. Surprisingly, geminin is not able to fully inhibit DNA licensing. However, CDK1/2-cyclin A can partially inhibit DNA licensing and, in conjunction with geminin, result in a complete block. These findings uncover geminin's steric inhibitory mechanism and suggest that a dual CDK-geminin axis controls human DNA replication.

Indexed as

Cell Cycle ProteinsDNA ReplicationGemininMinichromosome Maintenance Complex Component 2HumansMolecular Docking SimulationNuclear ProteinsOrigin Recognition ComplexProtein BindingCDC6 protein, humanCDT1 protein, humanCell Cycle ProteinsGemininGMNN protein, humanMCM2 protein, humanMinichromosome Maintenance Complex Component 2Nuclear ProteinsOrigin Recognition Complex

Identifiers

PMID41365879
PMCPMC12695944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.